You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

Investigational Drug Information for APG-1252

✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for APG-1252?

APG-1252 is an investigational drug.

There have been 8 clinical trials for APG-1252. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2022.

The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Endometrial Neoplasms. The leading clinical trial sponsors are Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd., and National Cancer Institute (NCI).

There are two US patents protecting this investigational drug and nineteen international patents.

Recent Clinical Trials for APG-1252
Testing the Combination of APG-1252 and Cobimetinib in Recurrent Ovarian and Endometrial CancersNational Cancer Institute (NCI)Phase 1
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaAscentage Pharma Group Inc.Phase 1/Phase 2
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsAscentage Pharma Group Inc.Phase 1

See all APG-1252 clinical trials

Clinical Trial Summary for APG-1252

Top disease conditions for APG-1252
Top clinical trial sponsors for APG-1252

See all APG-1252 clinical trials

US Patents for APG-1252

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
APG-1252 ⤷  Sign Up BCL-2/BCL-XL inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI) ⤷  Sign Up
APG-1252 ⤷  Sign Up Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.